Recent Updates
Recently added Catalysts
FMS

Fresenius Medical Care AG & Co. KGaA Investor Relations Investor News Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Te

Key Takeaway: Fresenius Medical Care AG & Co. KGaA Investor Relations Investor News Else-Kr ner-Str. 1 D-61352 Bad Homburg Contact: Oliver Maier Phone: + 49 6172 609 2601 Fax: + 49 6172 609 2301 E-mail: ir@fmc-ag.com North America: Terry L. Morris Phone: + 1 800 948 2538 Fax: + 1 6

Full Press Release Details

Fresenius Medical Care AG & Co. KGaA
Investor Relations
Investor News Else-Kr ner-Str. 1
D-61352 Bad Homburg
Contact:
Oliver Maier
Phone: + 49 6172 609 2601
Fax: + 49 6172 609 2301
E-mail: ir@fmc-ag.com
North America:
Terry L. Morris
Phone: + 1 800 948 2538
Fax: + 1 615 345 5605
E-mail: ir@fmc-ag.com
Internet: www.fmc-ag.com
Fresenius Medical Care Announces upgraded Rating of
Unsecured Debt Issues by Standard & Poor s
Homburg, Germany Fresenius Medical Care
AG & Co. KGaA ( the Company ), the world s largest provider
of Dialysis Products and Services, today reports that Standard & Poor s has
assigned upgraded debt and recovery ratings to the Company s unsecured debt
issues. Based on a recovery analysis the rating of Trust Preferred Securities
IV ($225 million) and Trust Preferred Securities V ( 300 million) improved to
BB from single B+. Additionally the rating of the $500 million Senior Notes due
2017 improved to BB+ from BB-. The corporate credit rating remains unchanged at
BB, the outlook is stable.
A. Rosen, Chief Financial Officer, commented: The Company welcomes the
improved ratings which reflect our strong global position in
growing, non-cyclical markets of the dialysis industry. The dialysis industry
is characterized by stable cash flows; most of the Company s customers have a
high credit rating. Furthermore, we have a proven ability to reduce debt significantly
over time. Our financial position is strong and we are confident
to meet our financial targets.
FRESENIUS MEDICAL CARE AG & Co. KGaA
Facility Year issued Amount in million New Rating Old Rating
Corporate Credit Rating BB BB
Credit Agreement Term Loan A 2006 $ 1,850 BBB- BBB-
Credit Agreement Term Loan B 2006 $ 1,750 BBB- BBB-
Secured Revolving Credit Facility 2006 $ 1,000 BBB- BBB-
Senior Notes 2007-2017 2007 $ 500 BB+ BB-
Trust Preferred Securities IV (subordinated notes) 2001 $ 225 BB B+
Trust Preferred Securities V (subordinated notes) 2001 300 BB B+
Fresenius Medical Care is the
world s largest integrated provider of products and services for individuals
undergoing dialysis because of chronic kidney failure, a condition that affects
more than 1,600,000 individuals worldwide. Through its network of 2,238
dialysis clinics in North America, Europe, Latin America, Asia-Pacific and
Africa, Fresenius Medical Care provides dialysis treatment to 173,863 patients
around the globe. Fresenius Medical Care is also the world s leading provider of
dialysis products such as hemodialysis machines, dialyzers and related
disposable products. Fresenius Medical Care is listed on the Frankfurt Stock
Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).
For more information about
Fresenius Medical Care visit the Company s website at www.fmc-ag.com.
This release contains
forward-looking statements that are subject to various risks and uncertainties.
Actual results could differ materially from those described in these
forward-looking statements due to certain factors, including changes in
business, economic and competitive conditions, regulatory reforms, foreign
exchange rate fluctuations, uncertainties in litigation or investigative
proceedings, and the availability of financing. These and other risks and
uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA s
reports filed with the U.S. Securities and Exchange Commission. Fresenius
Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking
statements in this release.
Last updated: Apr 2, 2008